Anatomic pathology studies performed over 150 years ago revealed that excessive
activation of coagulation occurs in the setting of inflammation. However, it has taken over a …

The tissue factor (TF) pathway plays a central role in hemostasis and thrombo‐inflammatory
diseases. Although structure‐function relationships of the TF initiation complex are …

INTRODUCTION Antiphospholipid antibodies (aPLs) transiently appear in infectious
diseases but can persist in primary antiphospholipid syndrome (APS) or in association with …

Immune evasion in the tumor microenvironment (TME) is a crucial barrier for effective cancer
therapy, and plasticity of innate immune cells may contribute to failures of targeted …

Tissue factor pathway inhibitor (TFPI) is an alternatively spliced anticoagulant protein that
primarily dampens the initiation phase of coagulation before thrombin is generated. As such …

Activated protein C (APC) is a multifunctional serine protease with anticoagulant,
cytoprotective, and anti-inflammatory activities. In addition to the cytoprotective effects of …

Safe and effective antithrombotic therapy requires understanding of mechanisms that
contribute to pathological thrombosis but have a lesser impact on hemostasis. We found that …

For many years, the attention on tissue factor (TF) in human pathophysiology has been
limited to its role as initiator of extrinsic coagulation pathway. Moreover, it was described as …

Activation of protease-activated receptor 1 (PAR1) by activated protein C (APC) and
thrombin elicits paradoxical cytoprotective and cytotoxic signaling responses in vascular …

Simple Summary The exploration of prognostic biomarkers in ovarian cancer (OC) persists
due to the daunting challenge of therapy resistance and poor patient outcomes …